Modality
Small Molecule
MOA
DLL3 ADC
Target
MDM2
Pathway
Incretin
MCCPNHPV
Development Pipeline
Preclinical
~Apr 2024
→ ~Jul 2025
Phase 1
Oct 2025
→ Jun 2027
Phase 1Current
NCT06331336
93 pts·PNH
2025-10→2027-06·Completed
93 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-05-192mo awayEMA Filing· PNH
2027-06-211.2y awayPh2 Data· PNH
Trial Timeline
Q42026Q2Q3Q42027Q2Q3
P1/2
Complet…
Catalysts
EMA Filing
2026-05-19 · 2mo away
PNH
Ph2 Data
2027-06-21 · 1.2y away
PNH
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06331336 | Phase 1/2 | PNH | Completed | 93 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| Rimamavacamten | Merck & Co | Phase 1 | PI3Kα | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| SRP-1135 | Sarepta | Phase 2/3 | MDM2 | |
| Tixatapinarof | Arvinas | Phase 1/2 | CDK2 |